首页> 外文学位 >Polyphyllin D activates mitochondrial and lysosomal apoptotic pathway in drug resistant RHepG2 cells.
【24h】

Polyphyllin D activates mitochondrial and lysosomal apoptotic pathway in drug resistant RHepG2 cells.

机译:多糖D激活抗药性RHepG2细胞中的线粒体和溶酶体凋亡途径。

获取原文
获取原文并翻译 | 示例

摘要

Cancer is one of the leading causes of death in the world. During cancer treatment, development of multidrug resistance (MDR) is always the major cause of failures of chemotherapy in human cancers. In our project, hepatocarcinoma HepG2 and its drug-resistant derivatives RHepG2 with MDR towards doxorubicin (Dox), fenretinide and Taxol were used to examine the differences in their response towards various anti-cancer agents.;Polyphyllin D (PD) is a saponin found in a tradition Chinese herb, Paris polyphylla, which has been used to treat liver cancers in China for many years. Interestingly, from the MTT assays, we found out that RHepG2 (IC50: 2.0 muM) was more sensitive towards PD when compared to that of its parental cells (IC50: 3.9 muM). To keep the MDR properties, RHepG2 cells were routinely cultured with 1.2 muM of Dox. When we cultured RHepG2 in the absence of Dox but with 1.2 muM of PD for 28 days, the Pgp expression could not be maintained. However, such high expression level of Pgp was maintained when RHepG2 cells were treated with vincristine (1.2 muM) in the absence of Dox. This indicates that vincristine was a substrate of Pgp to keep the Pgp expression in RHepG2 cells while PD was not.;Next, we investigated the underlying killing mechanism and found out that PD switched on both the mitochondrial and lysosomal apoptotic pathway in both cell lines. Our results indicate that PD was able to depolarize mitochondrial membrane potential and release apoptosis inducing factor (AIF) and cytochrome c (cyt c) from the mitochondria to cytosol. Also, PD was able to act on isolated mitochondria directly, causing a stronger mitochondrial membrane permeabilization and more AIF release from the RHepG2 than that of the parental cells.;By using the acridine orange (AO) staining method to examine the release of contents from lysosomes, it was found that PD released AO into the cytosol in both cell lines. However, the releasing pattern of HepG2 and RHepG2 was quite different. Upon PD treatment, the release of AO in HepG2 cells was graduate and slow while that in RHepG2 was sudden and sharp.;When incubated with different concentrations of Dox, RHepG2 accumulated less Dox than that of its parental HepG2 cells. When probed by the antibody against P-glycoprotein (Pgp), RHepG2 showed a strong Pgp expression. With the addition of Pgp modulator, verapamil, RHepG2 accumulated more Dox. All these findings indicate that Pgp is a mediator giving rise the MDR in RHepG2 cells. However, RHepG2 had a higher resistance to Dox than its parental line even co-cultured with verapamil. RHepG2 remained viable at the intracellular Dox concentration that was toxic to HepG2 cells. These observations suggest that the MDR properties of RHepG2 involved multiple mechanisms in addition to the effect of Pgp.;From the AO staining, most of the lysosomes were found in the cytosol near the nucleus. However, some lysosomes were found inside the nucleus occasionally. When we double stained the HepG2 cells with DiOC6(3), it was found that the lysosomes were actually located inside the nuclear tubules. However, no such lysosome migration was observed after treating the HepG2 cells with PD. Thus, lysosomes inside the nuclear tubules might not be involved in the PD-induced lysosomal pathway. The mechanism that leads to the migration of lysosomes into the nuclear tubules is still unclear.;From the Western blot analysis, cathepsin D (Cat D) and cathepsin L (Cat L) were both released from the lysosomes after treating the two cell lines with PD. Also, it seemed likely that Cat L was released earlier than that of cyt c. This implies that lysosomal permeabilization is an early event in apoptosis. With the use of siRNA technology, it was found that RHepG2 with the knockdown of Cat D and Cat L were more tolerant and vulnerable towards PD, respectively. These suggest that Cat D and Cat L might act oppositely in the apoptotic pathway. Furthermore, the addition of Cat D inhibitor, pepstatin A, blocked the PD-mediated cell death in RHepG2 cells further confirms that Cat D is a pro-apoptotic protein that is involved in the apoptotic pathway.;In conclusion, PD was a potent anti-cancer agent that could reverse the MDR properties of RHepG2 and kill more RHepG2 cells through lysosomal and mitochondrial apoptotic pathway.
机译:癌症是世界上主要的死亡原因之一。在癌症治疗期间,多药耐药性(MDR)的产生始终是人类癌症化疗失败的主要原因。在我们的项目中,使用肝癌HepG2及其对阿霉素(Dox),芬维A胺和紫杉醇具有耐多药耐药性的耐药衍生物RHepG2来检查它们对各种抗癌药的反应差异。;多叶素D(PD)是一种皂苷在一种传统的中草药巴黎七叶树中,它已在中国用于治疗肝癌多年。有趣的是,从MTT分析中,我们发现RHepG2(IC50:2.0μM)与其亲代细胞(IC50:3.9μM)相比对PD更敏感。为了保持MDR特性,常规将RHepG2细胞与1.2μMDox一起培养。当我们在没有Dox的情况下用1.2μMPD培养RHepG2 28天时,无法维持Pgp表达。但是,当在没有Dox的情况下用长春新碱(1.2μM)处理RHepG2细胞时,Pgp的这种高表达水平得以维持。这表明长春新碱是RHepG2细胞中Pgp表达的底物,而PD并非如此。接着,我们研究了潜在的杀伤机制,发现PD在两种细胞系中都同时激活了线粒体和溶酶体的凋亡途径。我们的结果表明,PD能够使线粒体膜电位去极化并从线粒体释放胞浆诱导因子(AIF)和细胞色素c(cyt c)到胞质溶胶。此外,PD能够直接作用于分离的线粒体,从而导致RHepG2的线粒体膜通透性增强,并且比亲代细胞从RHepG2释放出更多的AIF .;通过使用cr啶橙(AO)染色法检查从溶酶体,发现PD在两种细胞系中都将AO释放到胞质溶胶中。但是,HepG2和RHepG2的释放模式是完全不同的。经PD处理后,HepG2细胞中的AO释放缓慢而缓慢,而RHepG2中的AO则突然而尖锐。当与不同浓度的Dox一起孵育时,RHepG2的Dox积累要少于其亲本HepG2细胞。当用针对P-糖蛋白(Pgp)的抗体探测时,RHepG2显示出很强的Pgp表达。通过添加Pgp调节剂维拉帕米,RHepG2积累了更多的Dox。所有这些发现表明Pgp是介导RHepG2细胞中MDR升高的介质。但是,即使与维拉帕米共培养,RHepG2对Dox的抵抗力也比其亲本更高。 RHepG2在对HepG2细胞有毒的细胞内Dox浓度下仍保持活力。这些观察结果表明RHepG2的MDR特性除了Pgp的作用外还涉及多种机制。从AO染色中,大多数溶酶体在细胞核附近的细胞质中被发现。但是,偶尔在核内发现了一些溶酶体。当我们用DiOC6(3)对HepG2细胞进行双重染色时,发现溶酶体实际上位于核小管内部。然而,用PD处理HepG2细胞后,没有观察到这种溶酶体迁移。因此,核小管内的溶酶体可能不参与PD诱导的溶酶体途径。尚不清楚导致溶酶体迁移到核小管的机制。;从蛋白质印迹分析,组织蛋白酶D(Cat D)和组织蛋白酶L(Cat L)均在用溶酶体处理了两种细胞系后从溶酶体中释放出来。 PD。同样,Cat L似乎比cyt c的释放更早。这表明溶酶体通透性是细胞凋亡的早期事件。通过使用siRNA技术,发现敲除Cat D和Cat L的RHepG2分别对PD更具耐受性和脆弱性。这些提示Cat D和Cat L可能在凋亡途径中起相反的作用。此外,添加Cat D抑制剂胃蛋白酶抑制素A可以阻止RHepG2细胞中PD介导的细胞死亡,这进一步证实Cat D是一种参与凋亡途径的促凋亡蛋白。可以逆转RHepG2的MDR特性并通过溶酶体和线粒体凋亡途径杀死更多RHepG2细胞的抗癌剂。

著录项

  • 作者

    Lee, Kit Ying Rebecca.;

  • 作者单位

    The Chinese University of Hong Kong (Hong Kong).;

  • 授予单位 The Chinese University of Hong Kong (Hong Kong).;
  • 学科 Chemistry Biochemistry.
  • 学位 Ph.D.
  • 年度 2007
  • 页码 253 p.
  • 总页数 253
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号